Mounjaro week one: separating real side effects from TikTok hype

What did @anascstoree actually say?

Here's the problem: the transcript captured by the platform is garbled beyond usability. What we have is a string of incoherent phrases, "I will be able to get the balls" repeated several times, with no medically meaningful content extractable. The video caption, however, tells us something real. The creator describes their first week on Mounjaro 5mg, says they experienced "all possible side effects," and frames the experience as still being "my best choice." That framing, tolerating rough side effects and calling it worth it, is actually one of the more common and consequential narratives circulating around GLP-1 medications right now. With 541.9K views, even a caption-level claim carries weight.

Does the science back up the side-effect-heavy first week?

Yes, largely. The early weeks on tirzepatide are genuinely rough for a meaningful percentage of users, and the data reflects that. This is not just creator dramatics.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that gastrointestinal adverse events, primarily nausea, vomiting, diarrhea, and constipation, were reported by 44 to 51 percent of participants on tirzepatide across doses, with the highest rates occurring during dose escalation. The 5mg starting phase is exactly when these events cluster. A separate analysis of real-world GLP-1 tolerability (Wilding et al., 2023, Diabetes, Obesity and Metabolism) confirmed that discontinuation risk peaks in the first four weeks, largely because patients are not prepared for the intensity of early side effects.

So when the creator says they had "all possible side effects," that hyperbole aside, the underlying reality is well-documented. First-week tirzepatide side effects are not rare. They are expected, they are dose-related, and they do tend to improve with time for most patients who stay on the medication.

What did they get wrong, or right?

The creator gets something directionally right that a lot of GLP-1 content gets wrong: they do not pretend the experience was easy. Too much social media content around Ozempic and Mounjaro skips the side-effect reality entirely, leading people to expect a smooth ride. The caption's honesty about suffering through a difficult first week is more useful than polished before-and-after content that omits that part.

What we cannot evaluate, because the transcript is unusable, is whether the creator made any specific clinical claims in the video itself, dosing advice, comparisons to other medications, or claims about what the drug treats. We cannot confirm or deny those. What we can say plainly: the framing of "I had every side effect and it was still worth it" is not inherently dangerous, but it is a highly individual experience. For patients with certain GI conditions, a history of pancreatitis, or thyroid concerns, pushing through severe first-week side effects without medical guidance can be genuinely risky. Personal tolerance narratives should never substitute for clinical monitoring.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, not simply a GLP-1 drug, which is part of why its side-effect profile and efficacy data differ from semaglutide-only medications. The SURMOUNT-1 trial reported mean weight loss of 20.9 percent of body weight at the highest dose over 72 weeks, which is clinically significant. But that number comes from a controlled trial with monitoring, dose titration protocols, and exclusion criteria. It is not a ceiling or a promise for any individual user.

If you are starting Mounjaro or any tirzepatide product, the side effects described in this video are real and common. Nausea, fatigue, and GI disruption in week one are not signs the medication is failing or harming you. They are, in most cases, transient. However, severe or persistent vomiting, signs of pancreatitis (acute upper abdominal pain radiating to the back), or symptoms of hypoglycemia in patients also on insulin require immediate medical contact. A creator's caption saying it was "worth it" is not a clinical green light for you to white-knuckle through dangerous symptoms alone.

One more thing worth saying clearly: 5mg is the starting dose of Mounjaro, not a maintenance dose. Dose decisions belong to a prescriber who knows your full medical history, not to a TikTok comment section.

The bottom line on this video

The caption narrative is relatable and largely consistent with what clinical data shows about tirzepatide tolerability in week one. The transcript is unreadable, so we cannot fact-check the spoken content. The video's core premise, that Mounjaro's first week is rough but the creator sees it as worthwhile, is neither dangerous misinformation nor rigorous health guidance. It is a personal account with significant reach. The risk is not what the creator said. The risk is what 541.9K viewers might conclude without clinical context alongside it.